Revenues from our acute support line, which includes CentriMag and PediMag were $8.7 million compared with $4.4 million a year-ago, an increase of over 90%. We’re certainly pleased with the continued momentum in this product line, which include a growth in the core U.S. CentriMag business of 34% as well as approximately $2.7 million of incremental revenues recorded as a result of the Levitronix Medical transaction, over 90% of which were generate outside the U.S.Lastly, revenues from the Thoratec product line, the PVAD and IVAD were 5.8 million versus 7.3 million a year ago, a decrease of 21%. We recorded strong year-over-year unit growth in the quarter selling 1,057 pumps, an increase of 23% versus 859 pumps in the first quarter a year ago. In the U.S. market, we shipped 838 pumps representing a 24% year-over-year increase, while internationally pump volume increased 20% in the first quarter of 2012 to 219 units. HeartMate unit volume expanded by 32% in both the U.S. and international markets, offsetting a significant decline in PVAD and IVAD units.
Thoratec's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.